Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Antisense '97: A roundtable on the state of the industry

Nature Biotechnology volume 15, pages 519–524 (1997)Cite this article

As antisense drugs advance through clinical trials, is a “data gap” emerging between biotechnology companies, regulatory agencies, and academia?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antisense '97: A roundtable on the state of the industry. Nat Biotechnol 15, 519–524 (1997). https://doi.org/10.1038/nbt0697-519

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0697-519

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing